US-20260124263-A1 - Application, Extraction Method and Composition of Ganoderma lucidum Exosomes in Glioma Treatment

Abstract

This application relates to the technical field of biological products, and provides an application, extraction method and composition of TGL-ELNs in the treatment of glioma. The TGL-ELNs are applied in any one or more of the following aspects: a) Preparation of products for promoting apoptosis of glioma cells; b) Preparation of products for inhibiting proliferation of glioma cells; c) Preparation of products for inhibiting autophagy of glioma cells; d) Preparation of products for treating glioma. Verified through cell and animal experiments, the TGL-ELNs in this application can effectively induce apoptosis of glioma cells and inhibit autophagy of glioma cells to induce glioma cell death, and act on glioma cells through the AKT/mTOR signaling pathway and by inhibiting the production of autophagosomes in glioma cells.

Inventors

• Yilei XIAO
• Lei Wang
• Bingwu YANG
• Xiaofan Xu
• Lingyan DU
• Ping Wu
• Yawen ZHANG
• Xiaohui Zhang
• Hui Yue
• Zongqiang XU

Assignees

• Liaocheng people's hospital

Dates

Publication Date

20260507

Application Date

20251105

Priority Date

20241105

Claims (6)

1. 1 . An application of TGL-ELNs in any one or more of the following aspects: a) Preparation of drugs for promoting apoptosis of glioma cells; b) Preparation of drugs for inhibiting proliferation of glioma cells; c) Preparation of drugs for inhibiting autophagy of glioma cells; d) Preparation of drugs for treating glioma; The extraction method of the TGL-ELNs comprises the following steps: (1) Grinding the soaked Ganoderma lucidum to obtain a grinding solution; (2) Performing coarse filtration on the grinding solution to obtain a coarse filtrate; (3) Mixing the supernatant of the coarse filtrate after centrifugation with an enzyme preparation for enzymatic hydrolysis to obtain an enzymatic hydrolysate; (4) Performing impurity removal, filtration and concentration treatments on the enzymatic hydrolysate to obtain TGL-ELNs.
2. 2 . The application according to claim 1 , characterized in that, in the application of preparing drugs for inhibiting autophagy of glioma cells, the glioma treatment at least exhibits the following effects: inhibiting the autophagic pathway through the AKT/mTOR signaling axis and inhibiting the production of autophagosomes in glioma cells.
3. 3 . The application according to claim 1 , characterized in that the drug further comprises at least one pharmaceutically inactive ingredient.
4. 4 . The application according to claim 1 , characterized in that the administration objects of the drug are humans and non-human mammals.
5. 5 . The application according to claim 1 , characterized in that, in step (1), the soaking refers to soaking Ganoderma lucidum in PBS buffer solution; the soaking time is 2-24 hours; the enzyme preparation in step (3) comprises one or more of pectinase, cellulase, β-1, 3-glucanase and ligninase.
6. 6 . The application according to claim 1 , characterized in that, in step (3), the mass of the enzyme preparation used for enzymatic hydrolysis is 0.1-3% of the mass of Ganoderma lucidum ; the mass fractions of each component in the enzyme preparation are respectively 10-30% for pectinase, 30-50% for cellulase, 5-15% for β-1, 3-glucanase, and 20-40% for ligninase.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS This application claims foreign priority of Chinese Patent Application No. 202411562135.7, filed on Nov. 5, 2024 in the China National Intellectual Property Administration, the disclosures of all of which are hereby incorporated by reference. Technical Field This application relates to the technical field of biological products, and more specifically, to an application, extraction method and composition of TGL-ELNs □ Ganoderma lucidum (Taishan strain) exosomes □ in the treatment of glioma. Background Art As a traditional Chinese medicinal material with a long history of medicinal use, the extraction and application of active ingredients of Ganoderma lucidum have always been a research focus. Ganoderma lucidum and its polysaccharides (peptides) can directly act on mononuclear macrophages, dendritic cells and cytotoxic T cells in the body, promote the expression of TNFα mRNA and IFNγ mRNA, increase the production of TNFα and IFNγ, and enhance the activity of cytokines. This further inhibits the immune escape of tumor cells, thereby inhibiting tumor cell proliferation, inducing tumor cell apoptosis, and ultimately killing tumor cells. Therefore, the anti-tumor effect of Ganoderma lucidum does not act directly on tumor cells, and its anti-tumor effect is relatively limited. SUMMARY OF THE INVENTION The present application is provided to address the above-mentioned defects in the prior art. There is a need for an application, extraction method and composition of TGL-ELNs in glioma treatment. Verified through cell and animal experiments, the TGL-ELNs in this application can effectively induce glioma cell apoptosis, inhibit glioma cell autophagy, and induce glioma cell death. They act on glioma cells through the AKT/mTOR signaling pathway and by inhibiting the production of autophagosomes in glioma cells. The first aspect of the present application provides an application of TGL-ELNs in any one or more of the following aspects: a) Preparation of products for promoting apoptosis of glioma cells;b) Preparation of products for inhibiting proliferation of glioma cells;c) Preparation of products for inhibiting autophagy of glioma cells;d) Preparation of products for glioma treatment. The second aspect of the present application provides an extraction method for TGL-ELNs, which includes the following steps: (1) Grinding the soaked Ganoderma lucidum to obtain a grinding solution; (2) Performing coarse filtration on the grinding solution to obtain a coarse filtrate; (3) Mixing the supernatant of the coarse filtrate after centrifugation with an enzyme preparation for enzymatic hydrolysis to obtain an enzymatic hydrolysate; (4) Subjecting the enzymatic hydrolysate to impurity removal, filtration and concentration treatments to obtain TGL-ELNs. The third aspect of the present application provides a composition. The active ingredients of the composition include at least TGL-ELNs, and the composition has any one or more of the following applications: a) Promoting apoptosis of glioma cells;b) Inhibiting proliferation of glioma cells;c) Inhibiting autophagy of glioma cells;d) Treating glioma. The applications, extraction methods and compositions of TGL-ELNs in glioma treatment provided in each example of the present application have been verified by experiments. The results show that: TGL-ELNs can be taken up by glioma cells and enriched intracellularly; they can inhibit the proliferation of glioma cells, but have no proliferation-inhibiting effect on microglial cell lines and no obvious cytotoxicity to normal microglial cells; they have anti-glioma effect and the effect of inducing glioma cell apoptosis; they can effectively inhibit the occurrence of autophagy in glioma cells and further induce glioma cell death by means of the AKT/mTOR signaling pathway and inhibiting the production of autophagosomes in glioma cells, while showing no obvious cytotoxicity to normal microglial cells at the corresponding concentration; in addition, they also have good safety. BRIEF DESCRIPTION OF THE DRAWINGS In the drawings that are not necessarily drawn to scale, the same reference numerals may describe similar components in different views. The same reference numerals with letter suffixes or different letter suffixes may represent different instances of similar components. The drawings generally illustrate various embodiments by way of illustration rather than limitation, and are used together with the specification and claims to explain the claimed embodiments. Where appropriate, the same reference numerals are used throughout all drawings to refer to the same or similar parts. Such embodiments are illustrative and are not intended to be exhaustive or exclusive embodiments of the device or method. FIG. 1A shows the TEM of Taishan Ganoderma lucidum exosomes according to Example 1 of the present application; FIG. 1B shows the NTA detection results diagram of Taishan Ganoderma lucidum exosomes according to